Agile Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on Monday, November 7, 2022
Agile Therapeutics (Nasdaq: AGRX) announced it will report third quarter 2022 financial results after market close on November 7, 2022. Following the release, a live conference call and webcast will occur at 4:30 p.m. ET to discuss financial outcomes and provide a business update. Agile focuses on women's healthcare, offering innovative contraceptive solutions like Twirla®, a non-daily transdermal contraceptive system. Further details will be accessible through their website.
- None.
- None.
Live Conference Call and Webcast at 4:30 p.m. ET
PRINCETON, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report third quarter 2022 financial results after the market close on Monday, November 7, 2022. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss the Company’s financial results and provide a business update.
| Event | Agile Therapeutics Third Quarter 2022 Financial Results Conference Call |
| Date | Monday, November 7, 2022 |
| Time | 4:30 p.m. ET / 1:30 p.m. PT |
A live webcast of the conference call may be accessed via the Investor Relations portion of the Agile Therapeutics website at https://ir.agiletherapeutics.com/events-and-presentations. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call.
About Agile Therapeutics, Inc.
Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website, Twitter account (@agilether), and LinkedIn account.
FAQ
When will Agile Therapeutics announce their Q3 2022 financial results?
What time is Agile Therapeutics' conference call for Q3 2022 results?
How can I access the live webcast of Agile Therapeutics' Q3 2022 financial results?
What is the focus of Agile Therapeutics as a company?
